Transitioning to Nurtec (Rimegepant) for Migraine Prevention
You can transition your patient directly to Nurtec (rimegepant) 75 mg every other day for prevention while discontinuing Ubrelvy (ubrogepant) for acute use, and continue Topamax (topiramate) during the transition with reassessment after 2-3 months. 1
Transition Strategy
Immediate Steps
Start Nurtec 75 mg orally disintegrating tablet every other day for preventive therapy 1. The most recent 2025 ACP guidelines support CGRP antagonists-gepants like rimegepant for patients with inadequate response to other treatments 2. Since your patient has continued migraines despite current therapy, this indicates treatment failure warranting escalation.
Discontinue Ubrelvy immediately once starting Nurtec. The FDA label explicitly states that concomitant use of medications acting on the CGRP pathway is not permitted 1. Both drugs target the same receptor, and using them together provides no additional benefit while increasing cost and potential adverse effects.
Managing Topiramate
Continue topiramate during the initial transition period 3. The 2002 guidelines emphasize that preventive treatments require 2-3 months to manifest clinical benefit and should be given an adequate trial 3. Since your patient is already on topiramate, maintain it while initiating Nurtec to avoid destabilizing their current baseline.
Reassess after 8-12 weeks of Nurtec therapy 1, 4. The pivotal trial for rimegepant prevention showed maximal benefit during weeks 9-12, with a mean reduction of 4.3 migraine days per month 4. If Nurtec provides adequate control, consider tapering topiramate gradually to simplify the regimen and reduce polypharmacy-related adverse effects.
Acute Treatment During Transition
Prescribe a triptan plus NSAID combination for breakthrough migraines 2. The 2025 ACP guidelines strongly recommend combination therapy with a triptan and NSAID as first-line for moderate-to-severe acute migraine 2. Options include:
- Sumatriptan 50-100 mg + naproxen 500 mg
- Rizatriptan 10 mg + ibuprofen 400 mg
- Eletriptan 40 mg + naproxen 500 mg
Counsel the patient to use acute medication no more than 2 days per week (or 8-10 days per month for triptans) 2. Medication overuse headache develops with ≥10 days/month of triptan use or ≥15 days/month of NSAID use 2. This is a critical pitfall—patients transitioning to prevention often continue overusing acute medications, which undermines preventive efficacy.
Expected Timeline and Monitoring
Expect gradual improvement over 4-12 weeks 3, 5, 4. The rimegepant prevention trial showed progressive reduction in migraine days, with statistically significant differences emerging by week 9-12 4. Counsel your patient that immediate dramatic improvement is unlikely—this manages expectations and improves adherence.
Have the patient maintain a headache diary tracking:
- Number of migraine days per month
- Severity of attacks
- Acute medication use
- Functional disability
- Adverse effects
This objective data guides whether Nurtec is providing adequate benefit 3, 5.
Safety Considerations
Screen for contraindications before prescribing Nurtec 1:
- History of hypersensitivity to rimegepant (absolute contraindication)
- Severe hepatic impairment (avoid use)
- End-stage renal disease requiring dialysis (avoid use)
- Pregnancy/breastfeeding (discuss risks)
Monitor for hypertension and Raynaud's phenomenon 1. The FDA label includes warnings about new-onset or worsening hypertension and development of Raynaud's phenomenon with CGRP antagonists. Check blood pressure at follow-up visits. If Raynaud's symptoms develop (typically within 1.5 days of dosing), discontinue Nurtec immediately.
Review drug interactions 1:
- Avoid strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir)
- With moderate CYP3A4 inhibitors (e.g., fluconazole, verapamil), avoid another Nurtec dose within 48 hours
- Avoid strong/moderate CYP3A inducers (e.g., rifampin, carbamazepine, St. John's wort)
- With potent P-gp inhibitors (e.g., cyclosporine, quinidine), avoid another dose within 48 hours
Note that topiramate is not a significant CYP3A4 inducer at typical migraine prevention doses (50-200 mg/day), so no dose adjustment of Nurtec is needed.
Common Pitfalls to Avoid
Do not use Nurtec for acute treatment while also using it for prevention in the initial transition. While rimegepant is FDA-approved for both indications 1, starting both simultaneously complicates assessment of which indication is providing benefit. Focus on prevention first, then reassess acute needs.
Do not discontinue topiramate abruptly if you later decide to taper it. Topiramate requires gradual dose reduction (typically 25-50 mg decrements every 1-2 weeks) to minimize withdrawal symptoms and rebound headaches 6.
Do not continue Nurtec indefinitely without reassessment 3, 5. After 6-12 months of stability, consider whether continued prevention is necessary or if the patient can manage with acute treatment alone. The 2002 guidelines emphasize that preventive therapy should be tapered after a period of stability 3.
Cost Considerations
Nurtec has a high annual cost (approximately $5,994 for oral formulation) 2. The 2025 ACP guidelines note this is significantly more expensive than traditional preventives like topiramate. Verify insurance coverage and prior authorization requirements before prescribing. If cost is prohibitive, the 2025 ACP guidelines recommend prioritizing less costly options like topiramate, propranolol, or amitriptyline first 5.
However, since your patient has already failed topiramate (continued migraines despite use), escalation to a CGRP-targeted therapy is appropriate 2, 5. The 2021 Nature Reviews Neurology guideline supports CGRP monoclonal antibodies or gepants after failure of 2-3 traditional preventives 6.
Alternative Consideration
If insurance denies Nurtec or cost is prohibitive, consider switching to a CGRP monoclonal antibody (erenumab, fremanezumab, or galcanezumab) instead 6, 5, 7. The 2024 VA/DoD guidelines give these a strong recommendation for episodic or chronic migraine prevention 7. These require monthly or quarterly injections but may have better insurance coverage and similar efficacy to rimegepant 6, 4.